Explore our brands

Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges.
Contact
Chemical Biology | Industry Spotlights & Insight Articles

Targeting Novel E3 Ubiquitin Ligases: Carles Galdeano, Professor, University of Barcelona

Edited by Tom Cohen | 01 December 2023
We discuss working on PROTACs, targeting novel E3 ubiquitin ligases, and Dr Galdeano's spin out Oniria Therapeutics.

 

Like this interview? See more below:

 

Join and network with over 450 industry discovery biology and chemistry leaders at the renowned Drug Discovery Summit in Basel, where they address critical strategies in target identification, validation
and HIT optimisation of small and large molecule drugs.

Speaker Biographies

Dr Carles Galdeano is currently a Serra Hunter Lecturer Professor at University of Barcelona. He obtained his PhD in medicinal chemistry at University of Barcelona with two visiting stays at Virginia Tech (USA) and CNRS (France). After that, he spent three years post-doc in the Alessio Ciulli’s lab (first at University of Cambridge and later at University of Dundee) where together they develop the first potent VHL ligands described. His postdoctoral discoveries represented a breakthrough in the PROTACS field. In 2015, he returned to the University of Barcelona to work in collaboration with Prof Barril with a Beatriu de Pinos Fellowship until 2019, when he started his independent research group.

Related Resources

Alzheimer's & Brain Awareness Month Spotlight: How Amphista Therapeutics is Tackling Neurological Disorders

To honour Alzheimer's & Brain Awareness Month, this article will acknowledge Amphista Therapeutics' use of targeted protein degradation (TPD) to treat symptoms of neurological disorders.
Read More

New Class of Molecular Glues Could Reshape Cancer Drug Discovery

A research group at the University of Dundee discovered new molecular glues, expanding the targeted protein degradation field.
Read More